Teleflex paying up to $650 mln for privately-held Palette Life Sciences AB
Teleflex Inc. (TFX) said Wednesday it agreed to pay up to $650 million for privately-held urology and cancer treatment products maker Palette Life Sciences AB in a deal expected to close in the fourth quarter. The purchase price values Palette Life Sciences at about 11.6 times its estimated 2023 revenue of about $56 million, with projected revenue growth in the high-teens to low 20% range. Teleflex said the acquisition will be immediately accretive to adjusted gross margin. Teleflex said it expects the acquisition will be dilutive to its adjusted earnings per share in 2023 and add to its 2024 profit by about 15 cents to 5 cents a share. Teleflex stock is up 2.6% in 2023 compared to a 35.1% gain by the Nasdaq .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-26-23 0647ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing